1 / 14

Chimeric antigen receptor t cell therapy

Notably, several CAR-T libraries have been generated not only for blood cancer antigen CD19, but also for solid tumors against different antigens, such as Her2, Her3, EGFR, FGFR1, VEGFR, etc. The selected stable clones can be used in clinic trials immediately, thus making this technology more powerful and attractive in chimeric antigen receptor t cell therapy. https://www.creative-biolabs.com/car-t/cellrapeutics-chimeric-antigen-receptor-car-technology.htm

bellasmith123
Télécharger la présentation

Chimeric antigen receptor t cell therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chimeric Antigen Receptor TCell Therapy Reference: https://www.creative-biolabs.com/car-t/cellrapeutics-chimeric-antigen-receptor-car-technology.htm

  2. Contents 01 02 CAR-T Library Technology scFv Production in CAR Technology 04 03 Four Generations of CARs Application in Animal Models 05 06 Bispecific CAR Construction GMP Manufacturing and Clinical Trials

  3. scFv Production in CAR Technology The typical structure of a CAR molecule includes a single chain variable fragment (scFv), a spacer, a transmembrane domain (TM) and an intracellular signaling domain.

  4. scFv Production in CAR Technology The scFv is derived from monoclonal antibody (mAb), which can specifically recognize the target protein on tumor surface and subsequently transduct activation signal into CAR-T cell. With our one-stop solution, we can carry out scFv generation from hybridoma cell line (full length of monoclonal antibody) through the converting full immune globulin (monoclonal antibodies) into a scFv using a short flexible linker or phage display library which has nearly 1.0 × 108 individual candidate clones. Furthermore, synthesis a scFv gene based on the existed sequence from customer is also an available service.

  5. CAR-T Library Technology A state-of-the-art CAR-T library technology based on T cell display

  6. CAR-T Library Technology CAR genes with diverse antibody fragments (e.g. scFv, Fab, VHH, scFab) against a certain target are constructed into vectors to form the CAR-T libraries with capacity around 108. T lymphocytes will display these antibodies on the surface and high-throughput screening approaches can be performed. Due to the linkage between the T cell activation and the expression and function of the CARs, functional CARs are obtained with high affinities ranging from 10 pmol to nmol. The selected stable clones can be used in clinic trials immediately, thus making this technology more powerful and attractive in CAR-T cell immunotherapy.

  7. Four Generations of CARs There’re four generations of CAR products available

  8. Four Generations of CARs • The first generation CAR consisting of basic elements has been widely applied in early cancer immunotherapy clinical trials. • Different from the first generation which has one intracellular signaling domain like CD3ζ or or FcεRIγ, the second-generation CAR is composed of an activating domain plus a co-stimulatory signal domain such as CD28 or 4-1BB, the structure of which can support longer antitumor effect. • Similar to this strategy, two different co-stimulatory signaling regions are constructed into the third generation CARs in order to promote the T cell activation signal and enhance the proliferation and survival of CAR-T cells significantly. • Furthermore, the fourth generation CAR construct is engineered with an inducible expression unit such as a cytokine (like IL-12), which can effectively overcome the “on-target, off-tumor” drawbacks via this inducible transgenic cytokine gene.

  9. Application in Animal Models animal models (e.g. murine, canine and non-human primate (NHP)

  10. Application in Animal Models Up to now, CAR-T cells or -NK cells have been successfully developed and evaluated i terms of anti-tumor effect and potential safety profile in these animal cancer models, which can greatly support your preclinical trial researches. Meanwhile, these animal toxicity testing system can also identify and assess the safety profile of CAR modified T cells or NK cells, which including “on-target, off-tumor” toxicities targeting normal tissues and cytokine-release syndromes.

  11. Bispecific CAR Construction cocktail CAR, trans-dual specificity CAR and TanCAR

  12. Bispecific CAR Construction The cocktail CAR consists of two tandem scFvs connected by a linker, which can recognize two different tumor antigens so as to enhance the specificity and facilitate the activation of T cells, especially when one cancer antigen is downregulated or mutated. Alternatively, we can also coexpress two distinct CAR constructs simultaneously within T cells, such as trans-dual specificity CAR and TanCAR. With the help of these advanced approaches, we can greatly increase the specificity of CAR to tumor cells whereas decrease its toxicity to normal tissue.

  13. Thanks Reference: https://www.creative-biolabs.com/car-t/cellrapeutics-chimeric-antigen-receptor-car-technology.htm

More Related